Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for Monoclonal Antibodies
4.2.2 Increasing R&D investment in Oncology and Analytic Techniques
4.3 Market Restraints
4.3.1 Lack of Skilled Professionals
4.3.2 Availability of Other Chromatography Techniques
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Products
5.1.1 Columns
5.1.2 Resins
5.1.3 Buffers
5.2 By Sample Type
5.2.1 Monoclonal Antibodies
5.2.2 Vaccines
5.2.3 Others
5.3 End-User
5.3.1 Contract Research Organizations
5.3.2 Pharma and Biopharmaceutical Companies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio-Rad Laboratories, Inc.
6.1.2 General Electric
6.1.3 Sartorius AG
6.1.4 Tosoh Bioscience GmbH
6.1.5 Waters Corporation
6.1.6 KNAUER
6.1.7 Sepax Technologies, Inc.
6.1.8 Merck KGaA.
6.1.9 JNC Corporation
6.1.10 Geno Technology Inc., USA.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS